Compugen (CGEN) Total Non-Current Liabilities (2009 - 2026)
Compugen (CGEN) posted quarterly Total Non-Current Liabilities of $28.5 million for Q1 2026, down 23.76% year-over-year from $37.3 million in Q1 2025, and down 8.95% on a QoQ basis from $31.3 million in Q4 2025.
Compugen (CGEN) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Compugen has reported Total Non-Current Liabilities for 18 years, with the latest figure at $28.5 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $28.5 million, down 23.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.5 million (down 23.76% YoY), and the FY2025 annual result was $31.3 million, down 21.67% from the prior year.
- Total Non-Current Liabilities fell to $28.5 million in Q1 2026, from $31.3 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $39.9 million in Q4 2024 and troughed at $4.0 million in Q3 2023.
- A 5-year average of $21.3 million and a median of $28.5 million in 2026 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities tumbled 45.34%; it then surged 779.92% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $4.6 million in 2022, then soared by 544.72% to $29.5 million in 2023, then surged by 35.28% to $39.9 million in 2024, then dropped by 21.67% to $31.3 million in 2025, then slipped by 8.95% to $28.5 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $28.5 million in Q1 2026, $31.3 million in Q4 2025, and $33.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | 28.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.47 Mn |
| Dec 31, 2025 | 31.27 Mn |
| Sep 30, 2025 | 33.74 Mn |
| Jun 30, 2025 | 35.69 Mn |
| Mar 31, 2025 | 37.34 Mn |
| Dec 31, 2024 | 39.92 Mn |
| Sep 30, 2024 | 35.27 Mn |
| Jun 30, 2024 | 27.06 Mn |
| Mar 31, 2024 | 29.40 Mn |
| Dec 31, 2023 | 29.51 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 4.25 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 4.58 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Mar 31, 2022 | 7.08 Mn |
| Dec 31, 2021 | 8.37 Mn |
| Sep 30, 2021 | 7.22 Mn |
| Jun 30, 2021 | 7.55 Mn |